Ready To Make Bigger Biotech Investments, Vida Raises $600m For Second Fund

Scrip spoke with Fred Cohen, who co-founded Vida Ventures with former Kite Pharma CEO Arie Belldegrun, about the venture capital firm's investment focus after raising its second fund in two years.

Business development idea and developing industry success through creative invention as a light bulb evolving to a gear shape as a 3D illustration.
Vida's new fund will allow it to invest about $40m per company. • Source: Shutterstock

Vida Ventures raised two times as much money for its second venture capital fund than it did for its first fund less than two years ago, but it will invest in the same number of companies with its new $600m pool of cash, according to senior managing partner Fred Cohen. The larger fund will allow Vida to make bigger investments in each opportunity and make sure that its companies can reach their next value inflection point even if the economy shifts into a negative cycle.

Cohen co-founded Vida Ventures in 2017 with Arie Belldegrun, who was the CEO of Kite Pharma Inc. when the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.